DK3389653T3 - 2-iminobiotin til anvendelse i behandling af hjernecellelæsion - Google Patents

2-iminobiotin til anvendelse i behandling af hjernecellelæsion Download PDF

Info

Publication number
DK3389653T3
DK3389653T3 DK16825913.3T DK16825913T DK3389653T3 DK 3389653 T3 DK3389653 T3 DK 3389653T3 DK 16825913 T DK16825913 T DK 16825913T DK 3389653 T3 DK3389653 T3 DK 3389653T3
Authority
DK
Denmark
Prior art keywords
iminobiotin
treatment
brain cell
cell lesion
lesion
Prior art date
Application number
DK16825913.3T
Other languages
English (en)
Inventor
Paul Willem Theresia Josef Leufkens
Cacha Marie Pétronelle Cathérine Dorothée Peeters
Huibert Alexander Tjabbes
Original Assignee
Neurophyxia B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurophyxia B V filed Critical Neurophyxia B V
Application granted granted Critical
Publication of DK3389653T3 publication Critical patent/DK3389653T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK16825913.3T 2015-12-16 2016-12-16 2-iminobiotin til anvendelse i behandling af hjernecellelæsion DK3389653T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15200492 2015-12-16
PCT/NL2016/050880 WO2017105237A1 (en) 2015-12-16 2016-12-16 2-iminobiotin for use in the treatment of brain cell injury

Publications (1)

Publication Number Publication Date
DK3389653T3 true DK3389653T3 (da) 2024-01-02

Family

ID=54936830

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16825913.3T DK3389653T3 (da) 2015-12-16 2016-12-16 2-iminobiotin til anvendelse i behandling af hjernecellelæsion

Country Status (11)

Country Link
US (3) US10525039B2 (da)
EP (1) EP3389653B1 (da)
JP (1) JP6975165B2 (da)
AU (1) AU2016372396B2 (da)
CA (1) CA3008790A1 (da)
DK (1) DK3389653T3 (da)
ES (1) ES2965754T3 (da)
FI (1) FI3389653T3 (da)
PL (1) PL3389653T3 (da)
PT (1) PT3389653T (da)
WO (1) WO2017105237A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3389653T3 (da) 2015-12-16 2024-01-02 Neurophyxia B V 2-iminobiotin til anvendelse i behandling af hjernecellelæsion
WO2019157277A1 (en) * 2018-02-09 2019-08-15 Yale University Methods, systems and compositions for normothermic ex vivo restoration and preservation of intact organs
WO2022203505A1 (en) * 2021-03-23 2022-09-29 Neurophyxia B.V. 2-iminobiotin for use in the treatment of stroke
IL306094A (en) * 2021-03-23 2023-11-01 Neurophyxia B V 2-Iminobiotin for use in the treatment of stroke

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20043214B (en) 1999-01-21 2004-04-26 Bristol Myers Squibb Company Us Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7- Beta – Cyclodextrin or 2-Hydroxypropyl- Beta – Cyclodextrina and Pharmaceutical Compositions Containing the Same
US7087633B2 (en) 2000-03-31 2006-08-08 Universitair Medisch Centrum Method for treating perinatal asphyxia in a human or animal neonate
DK1280526T3 (da) 2000-03-31 2005-09-05 Univ Medisch Centrum Utrecht Anvendelse af 2-iminobiotin til fremstilling af et lægemiddel til forebyggelse og/eller behandling af komplikationer hos nyfödte som er opstået under födslen
US7319090B2 (en) 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
EP2076255A2 (en) 2006-10-04 2009-07-08 Neurokey A/S Use of hypothermia inducing drugs
US9023878B2 (en) 2010-05-26 2015-05-05 Neurophyxia B.V. 2-iminobiotin formulations and uses thereof
EP2852571A4 (en) * 2012-05-23 2015-11-25 Cellix Bio Private Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF MUCOSITIS
GB2504263B (en) 2012-06-08 2015-09-16 Gw Pharma Ltd Synergistic therapies for neuroprotection
US10092591B2 (en) * 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
DK3389653T3 (da) * 2015-12-16 2024-01-02 Neurophyxia B V 2-iminobiotin til anvendelse i behandling af hjernecellelæsion

Also Published As

Publication number Publication date
AU2016372396B2 (en) 2022-04-14
AU2016372396A1 (en) 2018-06-28
US10525039B2 (en) 2020-01-07
US20200338046A1 (en) 2020-10-29
JP6975165B2 (ja) 2021-12-01
US10722496B2 (en) 2020-07-28
PL3389653T3 (pl) 2024-02-26
WO2017105237A1 (en) 2017-06-22
US11426387B2 (en) 2022-08-30
JP2019501969A (ja) 2019-01-24
FI3389653T3 (fi) 2023-12-18
CA3008790A1 (en) 2017-06-22
ES2965754T3 (es) 2024-04-16
US20200147049A1 (en) 2020-05-14
EP3389653B1 (en) 2023-11-08
PT3389653T (pt) 2023-12-28
EP3389653A1 (en) 2018-10-24
US20190262316A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
IL257105A (en) Modified cells and methods of therapy
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
IL254734B1 (en) Modified t cells and methods of making and using the same
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
PL3265053T3 (pl) Sposoby leczenia skóry
DK3395354T3 (da) Plasminogen til anvendelse i behandling af diabetisk nefropati
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
EP3467091A4 (en) CELL PROCESSING SYSTEM
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3524255T3 (da) Sammensætning til behandling af acne
DK3391902T5 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
EP3215219C0 (en) SKIN TREATMENT SYSTEM
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose